1. Home
  2. Live Updates
  3. Mds

Live Breaking News & Updates on Mds

Stay informed with the latest breaking news from Mds on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mds and stay connected to the pulse of your community

Early Transfusions, Treatments May Improve Outcomes in Low-Risk MDS

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS.

Adam-zayac , Rutgers-cancer-institute , Journal-of-the-national-comprehensive-cancer-network , Rutgers-robert-wood-johnson-medical-school , Rwjbarnabas-health , National-comprehensive-cancer-network , Blood-cancer-drug-decreases-levels , Early-transfusions , Rutgers-robert-wood-johnson-medical , Early-transfusion , Patients-with-lower-risk , Low-risk-mds

NEET MDS 2022: Selective edit window opens today for application correction

NEET MDS 2022: Selective edit window opens today for application correction : Rashtra News #NEET #MDS #Selective #edit #window #opens #today #application #correction NEET MDS 2022 selection edit window opens today, April 20, 2022. Candidates who want to make changes in the image of the application form can follow the steps given below. National Board

National-board-of-examinations , National-board , Medical-sciences , Application , Correction , Edit , Education , Mds , Neet , Neet-mds , Opens

European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS

The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.



Japan , Bristol-myers-squibb , Monica-shaw , European-commission , European-union , European-markets , Mds , Luspatercept , The-european-commission ,

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

New-york , United-states , Sunil-iyer , Oncologic-drugs-advisory-committee , Meeting-of-the-oncologic-drugs-advisory-committee , Columbia-university-irving-medical-center , International-prognostic-scoring-system , Drugs-advisory-committee , Science-summit , New-york-city , D , Mds

UK's FTSE 100 lacklustre at open as energy stocks fall

DS Smith Plc (SMDS.LON): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock DS Smith Plc | London S.E.: SMDS | London S.E.

United-kingdom , Bengaluru , Karnataka , India , Britain , Mrigank-dhaniwala , Pranav-kashyap , Reuters , Peerless-aerospace-fastener , International-paper , Federal-reserve , Good-friday

Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023

The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.

Evolving-treatment-landscape , Myelodysplastic-syndromes , Clinical-trials , Key-takeaways , Mds , Mds-treatment , Myelodysplastic-syndromes-treatment , Lower-risk-mds , Ker-050 , Variant-allele-frequency , Luspatercept

Trial Evaluates Reduced Chemo Post-Stem Cell Transplant in Blood Cancers

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

United-states , Oregon , Jefferyj-auletta , Rachelj-cook , International-blood , Science-university , National-marrow-donor-program , Marrow-transplant-research , Oregon-health , National-marrow-donor , Clinical-trial-corner

Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS

Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.

Amy-dezern , Evolving-treatment-landscape , Myelodysplastic-syndromes , Claims-data , Patient-reported-outcomes , Mds , Mds-treatment , Myelodysplastic-syndromes-treatment , Ash-2023 , Real-world-outcomes , Luspatercept

Dr Gomez Arteaga on an Investigation of Orca-T Vs PTCy-Based HCT in Acute Leukemia and MDS

Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.

Alexandra-gomez-arteaga , Division-of-hematology , Medical-oncology , Weill-cornell , New-york-presbyterian-hospital , Cellular-therapy , Ransplantation-and-cellular-therapy-meetings , Onclive-tv , Conference , Cgvhd , Rcat- , Post-transplant-cyclophosphamide

Drug Duo Is Efficacious in Treating Posttransplant GVHD

Jakafi plus Ruzurock showed promise in treating graft-versus-host disease in patients who underwent undergone allogeneic hematopoietic cell transplantation.

New-england-journal , News , Mds , Graft-versus-host-disease ,